{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shen R"],"funding":["Clinical research project by Shanghai Jiao Tong University School of Medicine","Chang Jiang Scholars Program, Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support","National Key R&D Program of China","Clinical Research Plan of Shanghai Hospital Development Center","Samuel Waxman Cancer Research Foundation","National Natural Science Foundation of China","Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai","Talent (Class A) of Guangci Excellence Youth Plan","Shanghai Rising-Star Program","National Key Research and Development Program of China"],"pagination":["e70310"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12017895"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(4)"],"pubmed_abstract":["Background
CD19 chimeric antigen receptor (CAR) T-cell therapy is a potential treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The combination of targeted therapeutic strategies, particularly bruton tyrosine kinase inhibitor zanubrutinib and programmed death-1 inhibitor tislelizumab, may improve clinical outcomes and modulate the tumour microenvironment (TME).Methods
We studied patients with R/R LBCL who received response-adapted zanubrutinib plus tislelizumab upon CD19 CAR T-cell therapy between June 2021 and March 2023. Patients were treated with zanubrutinib daily from leukapheresis to day 28 post-infusion; those achieving complete response continued zanubrutinib monotherapy for 3 months, while partial responders received combined zanubrutinib for 3 "],"journal":["Clinical and translational medicine"],"pubmed_title":["Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study."],"pmcid":["PMC12017895"],"funding_grant_id":["KY2023727","YW20220022","GCQN-2019-A16","2022YFC2502600","82400222","SHDC2022CRD033","SHDC2020CR1032B","CARTFR-05","82400227","20152206","19QA145600","20152208","82130004","2017YQ075"],"pubmed_authors":["Cao WG","Yi HM","Dong Y","Weng XQ","Liu MK","Zhao WL","Li L","Xu PP","Wang L","Cheng S","Yan ZX","Zhang YL","Song Q","Shen R","Jiang XF","Wu W","Wang Y","Chen S","Sheng LS"],"additional_accession":[]},"is_claimable":false,"name":"Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.","description":"Background
CD19 chimeric antigen receptor (CAR) T-cell therapy is a potential treatment for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The combination of targeted therapeutic strategies, particularly bruton tyrosine kinase inhibitor zanubrutinib and programmed death-1 inhibitor tislelizumab, may improve clinical outcomes and modulate the tumour microenvironment (TME).Methods
We studied patients with R/R LBCL who received response-adapted zanubrutinib plus tislelizumab upon CD19 CAR T-cell therapy between June 2021 and March 2023. Patients were treated with zanubrutinib daily from leukapheresis to day 28 post-infusion; those achieving complete response continued zanubrutinib monotherapy for 3 months, while partial responders received combined zanubrutinib for 3 ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T21:08:37.748Z","creation":"2026-05-22T03:07:51.667Z"},"accession":"S-EPMC12017895","cross_references":{"pubmed":["40268516"],"doi":["10.1002/ctm2.70310"]}}